News and views

The British Journal of Cardiology is pleased to support the British Society of Heart Failure’s (BSH’s) important new campaign ‘Freedom from failure’. Its aim, according to the society, is to create "a movement to embed heart failure as a serious but treatable long-term condition into the consciousness of the public, policymakers and ultimately, healthcare systems"....

Author: Kevin Lafferty Publisher: Powerhouse Publications, 2021 ISBN: 978-1838349004 Price £7.73...

We report, with great sadness that our friend, Dr John Pittard, has died peacefully at home after a long illness, borne with incredible courage....

We are delighted to announce a partnership between the British Journal of Cardiology (BJC) and the Society of Cardiothoracic Surgery of Great Britain and Ireland (SCTS)....

We are delighted to welcome Professor Adrian Brady to our editorial board....

We are delighted to announce a partnership between the British Journal of Cardiology (BJC) and the British Society for Heart Failure (BSH)....

New perspectives in heart failure management and the development of the multidisciplinary workforce was the focus of the 23rd Annual Autumn Meeting of The British Society for Heart Failure (BSH) ‘2020 vision for heart failure’. Held on 26th–27th November 2020, the meeting was hosted for the first time in a virtual space, which resembled the traditional home of the conference, the QE II Centre in London. Dr Alexandra Abel reports selected highlights from the meeting....

Variations in surgical technique for permanent pacemaker implantation in West Midlands Dear Sirs, Around 34,000 permanent pacemakers are implanted in England annually.1 With an increasingly ageing population, the rate of implantation is rising at an estimated rate of 4.7% per decade.2 However, there are no standardised guidelines on the surgical techniques for permanent pacemaker insertion. This has led to variability in practice among cardiologists across the country....

Women face a 20% increased risk of developing heart failure or dying within five years after their first severe heart attack compared with men, according to new US research published in Circulation (DOI: 10.1161/CIRCULATIONAHA.120.048015). In addition, women were more likely than men to be older and have a more complicated medical history at the time of their heart attacks....

AstraZeneca’s sodium-glucose co-transporter-2 (SGLT2 inhibitor) dapagliflozin has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults with and without type 2 diabetes....